535 related articles for article (PubMed ID: 33818411)
1. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
[TBL] [Abstract][Full Text] [Related]
2. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Wooding DJ; Bach H
Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
[TBL] [Abstract][Full Text] [Related]
3. Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics.
Aviani JK; Halim D; Soeroto AY; Achmad TH; Djuwantono T
Rev Med Virol; 2021 Nov; 31(6):e2225. PubMed ID: 33621405
[TBL] [Abstract][Full Text] [Related]
4. Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19.
Al-Tawfiq JA; Arabi Y
Hum Vaccin Immunother; 2020 Dec; 16(12):2973-2979. PubMed ID: 32881641
[TBL] [Abstract][Full Text] [Related]
5. Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment.
Sheervalilou R; Shirvaliloo M; Sargazi S; Bahari S; Saravani R; Shahraki J; Shirvalilou S; Shahraki O; Nazarlou Z; Shams Z; Ghaznavi H
Blood Purif; 2022; 51(1):1-14. PubMed ID: 33789273
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma.
Deere JD; Carroll TD; Dutra J; Fritts L; Sammak RL; Yee JL; Olstad KJ; Reader JR; Kistler A; Kamm J; Di Germanio C; Shaan Lakshmanappa Y; Elizaldi SR; Roh JW; Simmons G; Watanabe J; Pollard RE; Usachenko J; Immareddy R; Schmidt BA; O'Connor SL; DeRisi J; Busch MP; Iyer SS; Van Rompay KKA; Hartigan-O'Connor DJ; Miller CJ
Microbiol Spectr; 2021 Dec; 9(3):e0139721. PubMed ID: 34817208
[TBL] [Abstract][Full Text] [Related]
7. Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study.
Wu Y; Hong K; Ruan L; Yang X; Zhang J; Xu J; Pan S; Ren L; Chen L; Huang C; Shang Y
Virol Sin; 2020 Dec; 35(6):768-775. PubMed ID: 32865701
[TBL] [Abstract][Full Text] [Related]
8. Emergence of ancient convalescent plasma (CP) therapy: To manage COVID-19 pandemic.
Dassarma B; Tripathy S; Matsabisa M
Transfus Clin Biol; 2021 Feb; 28(1):123-127. PubMed ID: 33285298
[TBL] [Abstract][Full Text] [Related]
9. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
[TBL] [Abstract][Full Text] [Related]
11. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.
Lindholm PF; Ramsey G; Kwaan HC
Semin Thromb Hemost; 2020 Oct; 46(7):796-803. PubMed ID: 32526774
[TBL] [Abstract][Full Text] [Related]
12. Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19.
Ripoll JG; Tulledge-Scheitel SM; Stephenson AA; Ford S; Pike ML; Gorman EK; Hanson SN; Juskewitch JE; Miller AJ; Zaremba S; Ovrom EA; Razonable RR; Ganesh R; Hurt RT; Fischer EN; Derr AN; Eberle MR; Larsen JJ; Carney CM; Theel ES; Parikh SA; Kay NE; Joyner MJ; Senefeld JW
mBio; 2024 May; 15(5):e0040024. PubMed ID: 38602414
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
14. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
[TBL] [Abstract][Full Text] [Related]
15. Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of
Han YJ; Lee KH; Yoon S; Nam SW; Ryu S; Seong D; Kim JS; Lee JY; Yang JW; Lee J; Koyanagi A; Hong SH; Dragioti E; Radua J; Smith L; Oh H; Ghayda RA; Kronbichler A; Effenberger M; Kresse D; Denicolò S; Kang W; Jacob L; Shin H; Shin JI
Theranostics; 2021; 11(3):1207-1231. PubMed ID: 33391531
[No Abstract] [Full Text] [Related]
16. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
17. COVID-19: benefits and risks of passive immunotherapeutics.
Gupta A; Karki R; Dandu HR; Dhama K; Bhatt ML; Saxena SK
Hum Vaccin Immunother; 2020 Dec; 16(12):2963-2972. PubMed ID: 32962524
[TBL] [Abstract][Full Text] [Related]
18. Passive immunization: Paradoxical and traditional method for new pandemic challenge COVID-19.
Iftikhar A; Jabeen F; Manzoor M; Younis T; Shaheen M
Acta Microbiol Immunol Hung; 2020 Jul; 67(2):87-90. PubMed ID: 32619190
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
[TBL] [Abstract][Full Text] [Related]
20. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]